Transdermal [Regulatives / Guidelines]

posted by Kelen – Brazil, 2020-06-29 18:51 (293 d 06:32 ago) – Posting: # 21605
Views: 758

Hi everyone,
In Brazil we are implementing the guideline about generic transdermal products and I have some doubts about the EMA Guideline.

(1) About the sensitisation and irritation test, is it dependent on how the medication is used or should it always be done as described in the guide, a patch every day even if the patch is to be used for more than 24 hours?

(2) Is a multiple dose study necessary if accumulation is observed or is there any other condition that would dispense this study with transdermal patches?

I would appreciate a lot any kind of help.
Thanks in advance!

Kelen

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 16 (0 registered, 16 guests [including 4 identified bots]).
Forum time: Monday 01:23 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5